Revenio Group Oyj - Half Year financial report

Revenio Group Corporation: Half Year Financial Report January 1 - June 30, 2016

Revenio Group Corporation

Half Year Financial Report January 1-June 30, 2016 (Unaudited)

Stock Exchange Release August 8, 2016 at 9:00 am

Revenio Group Corporation has adopted the publication procedure enabled by the
Financial Supervisory Authority's Regulations and guidelines 7/2013 (Disclosure
obligation on issuers) and is publishing its Half Year Financial Report for
January-June 2016 as an appendix to this stock exchange release. This release is
a summary of Revenio Group Corporation's Half Year Financial Report January-June
2016, which is available in full in the pdf file attached to this stock exchange
release, and on the company website at www.revenio.fi.

Second quarter net sales continued to grow, improving by almost 20% year-on-
year; operating profit up by nearly 13%

April-June 2016 in brief, continuing Group functions:

  * Strong net sales growth continued in the second quarter
  * Net sales totaled EUR 5.8 (4.9) million, showing an increase of 19.7 per
    cent.
  * Operating profit was EUR 1.7 (1.5) million, representing 28.7 per cent of
    net sales, an increase of 12.7 per cent
  * Salary costs have grown as a result of organizational growth. The increase
    was due to planned human resource investments required for the global sales
    launch of Icare HOME and Icare ic100 tonometers, and for the asthma and skin
    cancer product development projects.
  * Earnings per share, undiluted EUR 0.18 (0.14)
  * Sales permit for Icare ic100 granted in the United States
  * Revenio will have a new CEO as of January 1, 2017

January-June 2016 in brief, continuing Group functions:

  * Net sales amounted to EUR 11.0 (9.5) million, up by 16.4 per cent from the
    previous year
  * Operating profit was EUR 3.0 (2.9) million, representing 27.3 per cent of
    net sales, an increase of 3.5 per cent
  * Earnings per share, undiluted EUR 0.30 (0.30)

Key figures, continuing operations, EUR million:

            1.4-30.6.2016 1.4-30.6.2015 Change-     1.1.- 1.1-30.6.2015 Change-
                                              % 30.6.2016                     %

 Net sales,           5.8           4.9    19.7      11.0           9.5    16.4
 Group

 Operating
 profit,              1.7           1.5    12.7       3.0           2.9     3.5
 Group

 Net sales,
 Health               5.8           4.9    19.7      11.0           9.5    16.4
 Tech

 Operating
 profit,              2.1           1.9    12.9       3.7           3.6     4.2
 Health
 Tech

 Undiluted
 earnings            0.18          0.14    28.6      0.30          0.30     0.0
 per share

 Cash flow
 from                 1.2           0.9    29.6       1.2           4.0   -70.8
 operating
 activities

                                                  30 June  30 June 2015 Change,
                                                     2016               %-point

 Equity                                              79.3          79.0     0.3
 ratio-%

 Gearing-%                                          -24.3         -38.6    14.3



Financial guidance for 2016

Net sales growth is expected to remain strong. Profitability is expected to
remain at a healthy level despite growth investments.

Olli-Pekka Salovaara, President and CEO, comments on the second quarter of 2016:

"Our performance, both in terms of numbers and development projects, developed
as planned, with both EMEA and Latin America generating strong sales. Sales of
the Icare ic100 tonometer launched in Europe at the beginning of the year took
off well. In April, a sales permit was granted for the Icare ic100 in the United
States, and product launch is currently in progress. We expect this new-
generation product to accelerate sales in the US markets towards the year-end.

Icare is preparing to file a new sales license application to the FDA after the
completion of the feasibility study. The new application is expected to be filed
during 2016 as planned.

Probe sales continued to grow following growth in device sales and increasingly
active use of the devices.

Development projects involving skin cancer and asthma-related product concepts
are moving forward as planned. A prototype of a skin cancer diagnostic device is
currently being tested. I feel very confident about the future of these product
concepts."

Revenio Group Corporation
Board of Directors

For further information, please contact:
Olli-Pekka Salovaara, President & CEO, tel +358 40 5675520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin
for continuing operations standing at 28.4 %. Revenio Group Corporation is
listed on Nasdaq Helsinki.

[HUG#2033743]

Attachments:

Revenio Group Corporation Half Year Financial Report 2016.pdf